Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade

By M. Postow, R. Sidlow, M. Hellmann. New England Journal of Medicine, 2018

3,832 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis (2018, neutral): “Other 1 (2) 2 (6) 1 (8) 0 Abbreviations: CTLA-4, cytotoxic T lymphocyte antigen-4; PD-L1, programmed death ligand-1; PD-1, programmed death-1.”
Advances in immunotherapy for hepatocellular carcinoma (2021, background): “I.M. receives funding from MINECO SAF2014-52361-R and SAF 2017- 83267-C2-1R; Worldwide Cancer Research Grant (15-1146); the Asociacion Española Contra el Cancer (AECC) Foundation under grant GCB15152947MELE; and the European Union’s Horizon 2020 Program (grant agreement no. 635122 PROCROP).”
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022, background): “Apart from efficacy, it is concerned that dual PD-1/ PD-L1 and CTLA-4 blockade might lead to serious immune-related adverse events (irAEs) such as colitis, hypophysitis, pneumonitis, and thyroiditis [153].”
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. (2018, neutral): “6 Female 51 (27) 52 (208) 30 (11) 35 (52) ECOG performance status 0-1 70 (37) 92 (369) , .”